Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer

By afschroeder • August 5, 2026

Choueiri TK, Merchán J, Patnaik A, Drakaki A, Rini BI, Rha SY, Lee JL, Ornstein MC, Kumar R, Hwang C, Shao Y, Park SH, Barata PC, McGregor BA, Foster P, Chen J, Eisen M, Cole H, Weeder B, Guan Y, Singh J, Kaplan A, Cho S, Markus R, Kabbarah O, McKay RR. Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer. Nature. 2026 Aug 4. doi: 10.1038/s41586-026-10958-x. Epub ahead of print. Erratum for: Nature. 2026 Jul 1. doi: 10.1038/s41586-026-10718-x. PMID: 42552389.

Tags: Hematology/Oncology, Publications

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE

Rugo HS, Tolaney SM, Chan N, Borges G, Yerushalmi R, Sharifi MN, McHayleh W, Beck T, Vidula N, Hamilton E, Rinn KJ, O'Shaughnessy J, Curigliano[...]

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial

Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N,[...]

Novel Endocrine Therapies: Current Status and Future Directions

Brierley-Green E, Duggirala N, McCann KE, Callahan R, Bardia A, Lipsyc-Sharf M. Novel Endocrine Therapies: Current Status and Future Directions. Clin Breast Cancer. 2026 Aug[...]